Related Experiment Video

Updated: May 19, 2026

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
08:37

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Human positive coactivator 4 is a potential novel therapeutic target in non-small cell lung cancer

Y Peng1, J Yang, E Zhang

  • 1Institute of Combined Injury, State Key Laboratory of Trauma, Burns and Combined Injury, Research Center of Nanomedicine, College of Preventive Medicine, Third Military Medical University, Chongqing, China.

Cancer Gene Therapy
|August 25, 2012
PubMed

Insights

Transcriptional positive coactivator 4 (PC4) is upregulated in non-small cell lung cancer (NSCLC). Inhibiting PC4 shows therapeutic potential by reducing cancer cell growth and increasing apoptosis in preclinical models.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Transcriptional positive coactivator 4 (PC4) is a multifunctional nuclear protein involved in DNA processes.
  • The role of PC4 in cancer, particularly as a tumor suppressor, is debated.
  • Its specific role in non-small cell lung cancer (NSCLC) requires further investigation.

Purpose of the Study:

  • To investigate the role of PC4 in non-small cell lung cancer (NSCLC).
  • To determine if PC4 could serve as a potential therapeutic target for NSCLC.

Main Methods:

  • Immunohistochemical staining and western blotting on 104 human NSCLC specimens.
  • siRNA-mediated knockdown of PC4 in NSCLC cell lines (A549, H460, H358).
  • In vivo studies using A549 cell xenografts in mice treated with PC4 siRNA liposome complex.

Main Results:

  • PC4 protein expression was significantly upregulated in NSCLC tissues compared to adjacent noncancerous tissues.
  • PC4 knockdown inhibited NSCLC cell growth in vitro by inducing cell cycle arrest and apoptosis.
  • PC4 inhibition via siRNA liposome complex led to regression of NSCLC xenografts in mice, with reduced tumor growth and increased apoptosis.

Conclusions:

  • PC4 is upregulated in NSCLC and contributes to cancer cell proliferation.
  • Targeting PC4 represents a promising therapeutic strategy for non-small cell lung cancer.
  • PC4 inhibition effectively suppresses tumor growth and induces apoptosis in preclinical NSCLC models.

More Related Videos

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...